Macquarie Group
IMDZ

Macquarie Group’s Immune Design Corp. IMDZ Stock Holding History

Macquarie Group’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,000
Closed -$7K – 2341
2018
Q4 		$7K Buy
+5,000
New +$8.69K ﹤0.01% 2036
2018
Q1 		– Sell
-2,300
Closed -$9K – 2570
2017
Q4 		$9K Buy
+2,300
New +$12.5K ﹤0.01% 2295

Other funds holding IMDZ

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Macquarie Group's IMDZ Position: Q1 2019 in Review

Macquarie Group sold out of Immune Design Corp. (IMDZ) in Q1 2019, closing a stake of 5,000 shares — an estimated $7K sold.

Macquarie Group first reported a position in IMDZ in Q4 2017 and held it in 2 quarters. The position peaked at $9K in Q4 2017. 68 funds tracked by Wall St. Rank hold IMDZ as of Q1 2019.

  • Macquarie Group reported no remaining Immune Design Corp. position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 5,000 Immune Design Corp. shares in Q1 2019, an estimated $7K.
  • Macquarie Group first reported a position in Immune Design Corp. in Q4 2017 and held it in 2 quarters.
  • Macquarie Group's Immune Design Corp. position peaked at $9K in Q4 2017.
  • 68 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.